Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma?data from the Czech registry
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F12%3A%230000233" target="_blank" >RIV/00064190:_____/12:#0000233 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/12:00059259 RIV/00216208:11110/12:12165 RIV/61989592:15110/12:33141418 RIV/00209805:_____/12:#0000360 RIV/00064190:_____/12:#0000309
Result on the web
<a href="http://dx.doi.org/10.1093/annonc/mdr065" target="_blank" >http://dx.doi.org/10.1093/annonc/mdr065</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1093/annonc/mdr065" target="_blank" >10.1093/annonc/mdr065</a>
Alternative languages
Result language
angličtina
Original language name
Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma?data from the Czech registry
Original language description
Background: Sequential therapy with tyrosine kinase inhibitors (TKIs), sunitinib and sorafenib, is a common treatment choice for patients with advanced/metastatic renal cell carcinoma (mRCC) despite lack of randomised trials. The aim of this retrospective registry-based study was to analyse the outcomes of RCC patients treated with sunitinib? sorafenib or sorafenib?sunitinib sequence. Patients and methods: The Czech database containing information on patients treated for mRCC using targeted agents was used as a source of data for retrospective analysis. There were 138 patients treated with sunitinib? sorafenib sequence and 122 patients treated with sorafenib?sunitinib sequence. Results: Progression-free survival (PFS) was 17.7 months for patients treated with sunitinib?sorafenib sequence and 18.8 months for those receiving sorafenib followed by sunitinib (P = 0.47). Overall survival (OS) at 1 year was 83% [95% confidence interval (CI) 77% to 90%] for patients treated with sunitinib?sor
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
ANNALS OF ONCOLOGY
ISSN
0923-7534
e-ISSN
—
Volume of the periodical
23
Issue of the periodical within the volume
2
Country of publishing house
GB - UNITED KINGDOM
Number of pages
7
Pages from-to
395-401
UT code for WoS article
000299744400018
EID of the result in the Scopus database
—